RNAC Q2 2019 Earnings — Cartesian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

RNACCartesian Therapeutics, Inc.

$216M

Q2 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$13,000

Gross Profit

$13,000100.0% margin

Operating Income

-$16M-124884.6% margin

Net Income

-$16M-126107.7% margin

EPS (Diluted)

$-10.96

QoQ Revenue Growth

+30.0%

Cash Flow

Operating Cash Flow

-$7M

Free Cash Flow

-$7M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$47M

Total Liabilities

$47M

Stockholders' Equity

$56,000

Cash & Equivalents

$30M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$13,000	$0	—
Gross Profit	$13,000	$0	—
Operating Income	-$16M	-$19M	+13.5%
Net Income	-$16M	-$19M	+12.8%